A recent study by Charles River Associates reveals inequities in access to treatment for multiple sclerosis (MS) across Europe. A summary of key findings, with a link to the full report, can be found at the link below.
Keytruda & PD-(L)1: Life after programmed death (Part 3)
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...